Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer()()

BACKGROUND AND AIMS: BACKGROUND AND AIMSGemcitabine is the standard therapy for patients with pancreatic cancer with metastatic disease. Patients with metastatic pancreatic cancer presenting with increased values of C-reactive protein do not respond to gemcitabine. So far, no studies have evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Knoop, Richard F., Sparn, Moritz, Waldmann, Jens, Plassmeier, Lars, Bartsch, Detlef K., Lauth, Matthias, Hudemann, Christoph, Fendrich, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198747/
https://www.ncbi.nlm.nih.gov/pubmed/24953430
http://dx.doi.org/10.1016/j.neo.2014.05.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198747/
https://www.ncbi.nlm.nih.gov/pubmed/24953430
http://dx.doi.org/10.1016/j.neo.2014.05.010

Ejemplares similares